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Abstract: Silver nanoparticles (AgNPs) are promising alternatives to antibiotics. The aims of this
study were to produce AgNPs using two biological methods and determine their antibacterial activity
against Pseudomonas aeruginosa and Staphylococcus pseudintermedius. AgNPs were biosynthesized
from an infusion of Curcuma longa (turmeric) and the culture supernatant of E. coli. Characterization
was achieved by ultraviolet-visible spectroscopy and by Transmission Electron Microscopy (TEM).
The antibacterial properties of NPs from C. longa (ClAgNPs) and E. coli (EcAgNPs), alone and in
combination with carbenicillin and ampicillin, were investigated through the Kirby-Bauer disk
diffusion assay and the minimum inhibitory concentration (MIC). Dimensions of NPs ranged from
11.107 ± 2.705 nm (ClAgNPs) to 27.282 ± 2.68 nm (EcAgNPs). Kirby-Bauer and MIC assays showed
great antibacterial abilities for both NPs alone and in combination with antibiotics. EcAgNPs alone
showed the most powerful antibacterial activities, resulting in MIC values ranging from 0.438 ±
0.18 µM (P. aeruginosa) to 3.75 ± 3.65 µM (S. pseudintermedius) compared to those of ClAgNPs:
71.8 ± 0 µM (P. aeruginosa) and 143.7 ± 0 µM (S. pseudintermedius). The antibiofilm abilities were
strain-dependent, but no statistical differences were found between the two NPs. These results
suggest the antibacterial potential of AgNPs for the treatment of infectious diseases.
Keywords: antibiotic resistance; green synthesis; Pseudomonas aeruginosa; silver nanoparticles;
Staphylococcus pseudintermedius
1. Introduction
The introduction of nanoscale materials in the health industry is an emerging area of
nanotechnology [1–3]. In Europe, nanomaterials are defined as “natural, incidental or manufactured
material containing particles, in an unbound state or as an aggregate or as an agglomerate and where,
for 50% or more of the particles in the number size distribution, one or more external dimensions is in
the size range 1 nm–100 nm” [4].
The unique characteristics of silver nanoparticles are due to their surface-to-volume ratio that
considerably changes physical, chemical, and biological properties; for these reasons, these nanoparticles
have been used for various purposes [5], including textiles, keyboards, wound dressings, and biomedical
devices [6,7]. The size, shape, and surface coatings of nanoparticles are essential characteristics that
directly determine their biocidal activities [8]. Smaller particles have a larger surface to volume ratio
and, therefore, display greater toxic potential. A recent study found that the biological properties of
AgNPs strictly depend on the different surface charges of their coatings, which can affect the physical
interaction of AgNPs with microorganisms [9].
Many methods have been used for the synthesis of silver nanoparticles and nowadays, are
categorized as: (a) chemical methods; (b) physical methods and (c) biological methods.
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In the chemical methods, three main components, such as metal precursors, reducing agents, and
stabilizing/capping agents, are usually employed to produce metal nanoparticles [8,10,11]. The physical
approaches include direct interaction of laser or high voltage gate with raw metal, resulting in
immediate nanoparticles release [10,12]. To overcome the use of hazardous chemicals and the high
energy consumption required by previous described procedures, biological methods have emerged as
viable alternatives. The synthesis of AgNPs using green, cost-effective, and biocompatible methods
can be achieved by bacteria [13,14], fungi [15], and plant extracts [16–18].
Biological methods offer numerous advantages compared to both chemical and physical ones:
(a) proteins and secondary metabolites are released by living organisms in the synthesis process;
(b) elimination of steps to prevent particle aggregation; (c) eco-friendly and pollution-free characteristics
of biological molecules are used [8].
Silver (as silver ion) has been used as an antibacterial agent for centuries until the discovery of
modern antibiotics. Today, the global spread of bacteria resistant to the most common antibiotics
redirects the scientific research to alternative strategies able to fight also against multi-drug resistant
(MDR) bacteria. Silver nanoparticles (AgNPs) have become a target for researchers due to their
antimicrobial efficacy against bacteria, fungi, and viruses. In the literature, the antibacterial properties
of AgNPs against S. aureus, E. coli, P. aeruginosa, and S. typhi are described by different authors [5,18,19].
The antibacterial actions exerted by AgNPs are linked to: (a) adhesion to the cell wall, (b) penetration
and damaging of cytoplasmatic organelles; (c) induction of oxidative stress via reactive oxygen species
(ROS) production; (d) modulation of signal transduction pathways (e.g., stress response pathway) [20].
The dissemination of antibiotic-resistant bacteria is a global and rapidly emerging problem. In reptiles,
one of the most isolated bacteria is P. aeruginosa, often displaying resistance to multiple veterinary prescribed
antibiotics [21]. In dogs, S. pseudintermedius is considered one of the main causative agents of canine
pyoderma able to carry Staphylococcal Cassette Chromosome mec (SCCmec), coding for methicillin
resistance, and being able to produce several virulence factors, including biofilm [22].
The specific aims of this study are: (a) the set-up and optimization of protocols for the synthesis
of silver nanoparticles using two biological methods and (b) the analysis of their antibacterial and
anti-biofilm properties against P. aeruginosa and S. pseudintermedius strains isolated from animals.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
The bacterial strains used to study the antibacterial ability of AgNPs were randomly chosen from
the bacterial collection of the Microbiology Laboratory of the Department of Veterinary Medicine of
the Università degli Studi di Milano. Ten strains of P. aeruginosa were isolated from eyes lavages of
Chameleons (Furcifer pardalis); sheep blood agar and Cetrimide agar (Oxoid, Italy) were used to isolate
and verify bacterial isolates belonging to Pseudomonas aeruginosa species. Ten multi-drug-resistant
(MDR) S. pseudintermedius strains were isolated from canine pyoderma and characterized phenotypically
and genetically using, respectively, Mannitol Salt Agar (Microbiol, Italy) and the amplification of
thermonuclease (nuc) gene as reported previously [23]. The antibiotic resistance profiles of each strain
were assessed before this study with the Kirby-Bauer disk diffusion method; all the isolates were
tested for amoxicillin + clavulanic acid (30 µg), amoxicillin (10 µg), ampicillin (10 µg), cephalexin
(30 µg), cefovecin (30 µg), ceftiofur (30 µg), ceftriaxone (30 µg), clindamycin (10 µg), lincomycin +
spectinomycin (15 µg), doxycycline (30 µg), enrofloxacin (5 µg), marbofloxacin (5 µg), pradofloxacin
(5 µg), amikacin (30 µg), gentamicin (30 µg), neomycin (30 µg), tobramycin (30 µg), kanamycin (30 µg),
rifampicin (30 µg), azithromycin (15 µg), erythromycin (30 µg). P. aeruginosa strains were also tested
for carbenicillin (100 µg). All the strains were stored in 25% glycerol (Carlo Erba, Italy) at −20 ◦C until
use. However, before use, samples were thawed at room temperature and 10 µL was plated on Tryptic
Soy Agar + 1% sheep blood (Microbiol, Italy) and incubated aerobically at 37 ◦C for 24 h. Three or four
isolated colonies were picked up and used to assess the antibacterial activity of silver nanoparticles.
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2.2. Biosynthesis of AgNPs Using Curcuma Longa Extract
2.2.1. Preparation of C. longa Extract
The C. longa powder (turmeric) was kindly provided by Dr. G. Graziani (Farmacia Graziani, Italy).
The production of C. longa extract was assessed using a protocol found in the literature (Shameli et al.,
2012) with some modifications. Briefly, after dissolving 0.1 g of Curcuma powder in 20 mL of double
distilled sterile water (ddH2O) the solution was stirred for 4 h at room temperature in dark conditions
and filtered (Whatman® Grade 42, Ashless Filter Paper, Milan, Italy) to remove debris. This solution
was used to synthesize the nanoparticles.
2.2.2. Synthesis and Purification of Silver Nanoparticles
Forty millilitres of 1% AgNO3 (Carlo Erba, Italy) was added to the fresh Curcuma extract and
mixed (at 200 rpm) for 24 h in the dark (to avoid photochemical reactions) and at room temperature.
The reduction of Ag+ to Ag0 was monitored by checking the change in colour of the solution: from a
clear yellow to a progressive brown, as found in the literature [16,18,24]. To remove Ag+, the solution
was centrifuged at 4000 rpm for 20 min (Sigma 4-16 KS, Merck, Milan, Italy); the supernatant was
discarded and replaced with the same volume of sterile ddH2O. This step was repeated three times.
The purified nanoparticles were stored at room temperature in dark conditions and sonicated (30 kHz;
SONICS Vibra cell, Sonics, Newtown, UK) immediately before the assays, three times for 15 s on and
45 s off. The nanoparticles derived from C. longa synthesis were referred to as ClAgNPs.
2.3. Biosynthesis of AgNPs Using a Cell-Free Extract of E. coli
2.3.1. Preparation of Cell-Free Extract
The bacterial strain E. coli ATCC® 25922 was used to synthesize silver nanoparticles. For the
preparation of cell-free extract, the same conditions as those described by Kushawa et al. (2015) were
used. Briefly, E. coli ATCC® 25922 was cultured in Mueller-Hinton broth (Oxoid, Italy) and incubated
aerobically at 37 ◦C until reaching the logarithmic phase of growth (assessed by spectrophotometric
reading at 550 nm). The biomass was removed from the supernatant by centrifugation at 4000 rpm for
20 min (Sigma 4-16 KS); the liquid phase was filtered (0.22 µm syringe filter, Minisart® Sartorius, Merck,
Milan, Italy) to obtain the cell-free supernatant. To be sure about the absence of any residual bacteria
in the supernatant, 10 µL was plated on Plate Count Agar (PCA, Condalab, Spain) and incubated
aerobically at 37 ◦C for 24 h.
2.3.2. Synthesis and Purification of Bacterial Silver Nanoparticles
Synthesis of AgNPs was carried out according to a method described previously [25,26]. A 1%
AgNO3 (Carlo Erba, Italy) solution was added to the cell-free extract and incubated by shaking
(200 rpm) for 24 h in a dark environment at 37 ◦C. The synthesized nanoparticles were centrifuged at
4000 rpm for 20 min (Sigma 4–16 KS) to remove the Ag+ and resuspended in ddH2O. This step was
repeated three times. The nanoparticles derived from E. coli were referred to as EcAgNPs.
2.4. Characterization of AgNPs
The characterization of purified nanoparticles was carried out using two of the most used methods
reported by different authors [5,18,24,25,27].
2.4.1. Ultraviolet-Visible Spectroscopy (UV-vis)
Bio-reduction of Ag+ to Ag0 was monitored by measuring the absorption spectra (UV-vis) with a
spectrophotometer (SpectraMax 340 PC, Molecular Devices, Munich, Germany) collecting spectra over a
range of 310 to 770 nm (with an optical path length of 50 nm). Readings were recorded twice within 15 min.
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2.4.2. Transmission Electron Microscopy (TEM)
Size analysis of colloidal silver was characterized by EFTEM Leo 912ab (Zeiss, Milan, Italy) at a
voltage of 100 kV. The samples were briefly sonicated (30 kHz, 15 s on and 45 s off), and immediately,
a drop of the aqueous suspension of AgNPs was mounted on a carbon grid, which was placed on a
filter paper to absorb the excess of solvent. The morphological analysis (particle diameter and size
distribution) was calculated with Java image tool software (Image J2, v. 150).
2.5. Antimicrobial Properties
2.5.1. Kirby–Bauer Disk Diffusion Assay
The antimicrobial activities of both ClAgNPs and EcAgNPs were tested against the 10 P. aeruginosa
and 10 S. pseudintermedius strains and compared with antibiotics (carbenicillin and ampicillin, alone and
in synergistic combination with silver nanoparticles) using the agar disk diffusion assay. Carbenicillin
(Liofilchem, Roseto degli Abruzzi, Italy, 100 µg) was used against P. aeruginosa and ampicillin (Oxoid,
10 µg) against S. pseudintermedius. Briefly, after plating each strain on a sterile Mueller-Hinton agar
plate (Oxoid, Italy), antibiotics and virgin disks were placed on the plates. In detail: two sterile
disks were loaded with 20 µL of silver nanoparticles, two disks with antibiotics and two disks with
antibiotic supplemented with 20 µL of silver nanoparticles, one disk was used as a negative control.
All experiments were done in aseptic conditions in a laminar airflow cabinet, and two replicates were
done for each strain. The plates were incubated aerobically at 37 ◦C for 24 h. Zones of inhibition for
AgNPs, antibiotics, and antibiotics + nanoparticles were measured and expressed in millimetres (zone
of inhibition ± SD).
2.5.2. MIC
The minimum inhibitory concentration (MIC) was determined using the microdilution assay,
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2017). Briefly, all the
strains were grown on Brain Heart Infusion agar (BHI, Scharlau, Milan, Italy,) and three or four colonies
were suspended in fresh sterile saline solution to reach an initial concentration of 1.5 × 108 CFU/mL.
One hundred microliters of the 1:100 diluted cell suspensions was dispensed into each well of a 96-well
microtiter plate. The 10 strains of P. aeruginosa were exposed to twofold dilution series of NPs alone and
in synergistic combination (1:1 ratio) with carbenicillin. The same was done for S. pseudintermedius strains
except for ampicillin instead of carbenicillin. To rule out that the antibacterial activity may be exerted by
AgNO3 instead of AgNPs, MIC for AgNO3 was also performed (data not shown).
After incubation for 24 h at 37 ◦C, the MICs were determined as the lowest dilution of nanoparticles
able to inhibit visible bacterial growth.
2.6. Antibiofilm Properties
2.6.1. Screening for the Biofilm-Forming Ability
In a preliminary study (Figure S1), the biofilm-forming ability of the P. aeruginosa and
S. pseudintermedius strains was studied using a microtiter plate assay (MtP) [28,29]. As a negative
control, TSB + 1% glucose (TSBg) without bacteria was used. Each strain was tested in triplicate on
three independent plates. Briefly, fresh overnight subcultures of the strains were 1:100 fold diluted
in TSBg, and 200 µL were plated. After 24 h at 37 ◦C, the supernatant was gently removed and the
biofilm was washed with sterile phosphate-buffered saline (PBS), fixed with methanol, and stained
with 2% crystal violet. The absorbance (550 nm) of negative controls was used to set the optical density
cut-off (ODc) as three standard deviations above the mean OD of the negative controls. Strains were
classified as follows: non-adherent OD ≤ ODc; weakly adherent ODc < OD 97 ≤ 2 × ODc; moderately
adherent ODc < OD ≤ 4 × ODc; strongly adherent OD > 4 × ODc. Only the biofilm-producer strains
were used to study the anti-biofilm properties of silver nanoparticles.
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2.6.2. Interaction between AgNPs and Mature Biofilm
To determine the ability of both ClAgNPs and EcAgNPs to disrupt mature biofilm, an MtP assay
using a volume of 190 µL of bacteria culture (after 1:100-fold final dilution), and 10 µL of AgNPs was
carried out. The non-treated bacteria (NT) group was used to make a comparison with treated bacteria.
Using the above-described method [28], biofilm was grown at 37 ◦C for 24 h, then, 10 µL of
nanoparticles was added, and the plates were further incubated for 24 h. The disruptive ability of
the nanoparticles was determined by staining the biofilm biomass with crystal violet and measuring
the absorbance at 550 nm (Labsystem Multiscan Plus, ThermoFisher Scientific, Milan, Italy). Each
experiment was replicated three times per strain, and three independent plates were used.
2.7. Statistical Analysis
The statistical analysis, together with the graphical representation, were performed with GraphPad
Prism version 7.00 for Windows (GraphPad Software®, San Diego, CA, USA, www.graphpad.com).
To verify the normality (or non-normality) of the distributions, the following tests were performed:
D’Agostino and Pearson omnibus normality test, Shapiro–Wilk normality test, and Kolmogorov–Smirnov
normality test. For non-parametric distributions, the Mann–Whitney test was used to compare groups,
otherwise the standard Student’s t-test. The results are presented as follows: means± SD for disc diffusion
assay; µM ± SD for MIC; OD ± SD for anti-biofilm activity. All data were tested for normality and
analyzed using Student’s t-test and a p-value less than 0.05 was considered statistically significant.
3. Results
3.1. Synthesis of AgNPs
The change in colour (darkish-brown) of the silver solutions was used to monitor the bio-reduction
of silver ions to silver nanoparticles (Figure 1). The intensity of brown increased over the time, as found
in the literature. C. longa solution showed a more explicit darkish-brown appearance after the period
of incubation (Figure 1A). On the contrary, the supernatant of E. coli turned immediately from yellow
to yellow-white appearance without showing a brown aspect (Figure 1B). The confirmation of NPs
synthesis and stability was monitored by UV-Vis spectroscopy, while the morphological analysis was
performed with TEM.
Figure 1. Biosynthesis of silver nanoparticles. Plant-mediated method (A) after dissolving C. longa
powder in ddH2O, the solution was filtered to remove the majorities of vegetal debris; finally, silver
nitrate was added and the change in colour was monitored. Bacterial supernatant method (B). After
growing E. coli ATCC® 25922 in Mueller-Hinton broth, the supernatant was collected, and silver nitrate
was added to induce nanoparticle synthesis.
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3.1.1. UV-Vis Spectroscopy
UV-Vis spectroscopy is considered one of the most important tools for the evaluation of NPs
synthesis [24]. The absorption spectra of the AgNPs are shown in Figure 2. ClAgNPs showed a
clear absorption peak at around 440 nm, confirming the production of colloidal silver nanoparticles.
On the other hand, EcAgNPs showed a logarithmic-like curve which does not clearly show a specific
absorption peak or suggest any NPs formation. To exclude instrumental bias, serial dilutions of
EcAgNPs were loaded in the spectrophotometer with the same results in terms of peak’s absence.
Figure 2. UV-Vis spectroscopy of ClAgNPs (A) and EcAgNPs (B).
3.1.2. Size and Morphology Analysis of Silver Nanoparticles
Figure 3 shows the morphological analysis of silver nanospheres. It can be observed that NPs
obtained with Curcuma showed a spherical symmetry and heterogeneous spatial dimensions ranging
from 10 to 25 nm (11.1 ± 2.75 nm) (Figure 3A,C). The presence of narrow particles was in accordance
with the UV-Vis results.
Figure 3. Morphological analysis by TEM. (A,C) NPs derived from C. longa showed roughly spherical
morphology and mean diameter of 11.1 nm. (B,D) EcAgNPs showed a highly-branched symmetry and
dimension of 27.28 nm in diameter.
Vet. Sci. 2020, 7, 12 7 of 12
The analysis of E. coli supernatant showed nanoparticles enclosed in a matrix that connected each
particle to the other (Figure 3B). These particles had a roughly spherical morphology and diameter
ranging from 15 nm to 35 nm (27.28 ± 2.68 nm).
Overall, for both ClAgNPs and EcAgNPs, the results are in accordance with the literature [8,30],
confirming that biological methods for the synthesis of AgNPs produce nanoparticles lacking homogeneity.
After the morphological analysis, the estimation of the molar silver nanospheres concentration
was determined, as reported in the literature [14,31].
3.2. Antibacterial Activity
3.2.1. Kirby-Bauer Disk Diffusion Assay
The potential synergistic effects of combining silver nanoparticles with antibiotics were evaluated
with the disk diffusion assay (Figure 4). All the P. aeruginosa and staphylococcal strains were,
respectively, resistant to carbenicillin and ampicillin. The antibacterial activity of both ClAgNPs and
EcAgNPs increased when in combination with antibiotics in all the tested strains, showing significant
differences (p < 0.05) in comparison with silver nanoparticles alone. For P. aeruginosa strains (Figure 4),
ClAgNPs and EcAgNPs alone showed a mean inhibition halo of 9.5 and 14.4 mm, respectively, resulting
in statistical differences when compared to carbenicillin + ClAgNPs (14 mm), and carbenicillin +
EcAgNPs (17.45 mm). For S. pseudintermedius strains (Figure 4B), statistically differences were found
between ClAgNPs and EcAgNPs alone (12.8 mm, and 16.4 mm, respectively), and in combination with
ampicillin (19.61 mm, and 21.38 mm, respectively). The interpretation of Kirby-Bauer assay, using CLSI
breakpoints, showed that all the staphylococcal strains were considered resistant to ampicillin even
after the synergistic combination with NPs (resistance for ampicillin is <29 mm), while P. aeruginosa
strains were resistant against carbenicillin alone, but when NPs were added, the strains were susceptible
(resistance for carbenicillin is <17 mm).
The statistical differences between the two nanoparticles tested are shown in Figure 4, giving
reasons to hypothesize a better antibacterial ability of EcAgNPs, but only in staphylococcal strains.
This result is in contrast with the literature in which Gram-negative bacteria were reported as being
more susceptible to silver nanoparticles than Gram-positive, depending on differences in their cell
wall structure.
Figure 4. Disk Diffusion Assay. Effect of NPs used alone and in synergistic combination with
(A) carbenicillin against P. aeruginosa and (B) ampicillin against S. pseudintermedius. Statistical analysis
showed differences between inhibition halos of silver nanoparticles alone and those of silver in
combination with carbenicillin and ampicillin. In S. pseudintermedius strains, EcAgNPs have a larger
antibacterial effect compared to ClAgNPs. Results are presented as mean ± SD (* p value: 0.05–0.01;
** p value: <0.01; *** p value: <0.001).
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3.2.2. MIC
MIC (Table 1 and Figure 5) of each tested strain was determined for both ClAgNPs and
EcAgNPs alone and in synergistic combination with carbenicillin (for P. aeruginosa) and ampicillin (for
S. pseudintermedius). As found in the Kirby-Bauer assay, both P. aeruginosa and S. pseudintermedius were
resistant to carbenicillin (512 µg/mL) and ampicillin (56 ± 40.63 µg/mL). The results of NPs showed that
MIC were different between Gram-negative and Gram-positive bacteria. When the antibiotics were
adjuvated (1:1 ratio) with ClAgNPs and EcAgNPs, the MIC were significantly lower for both P. aeruginosa
and S. pseudintermedius, resulting in susceptible profiles only for Pseudomonas strains (according to CLSI
breakpoints). For both Gram-positive and Gram-negative bacteria, significant differences were found
comparing the same antibiotic adjuvated with ClAgNPs and EcAgNPs and showing a lower MIC (better
antimicrobial activity) for nanoparticles synthesized from E. coli supernatant.
Table 1. Determination of MIC values for ClAgNPs and EcAgNPs alone and in combination with
antibiotics. (carbenicillin 512–1µg/mL for P. aeruginosa; ampicillin 256–0.5µg/mL for S. pseudintermedius).
P. aeruginosa S. pseudintermedius
Antibiotic (µg/mL) 512 ± 0 56 ± 40.63
ClAgNPs (µM) 71.8 ± 0 143.7 ± 0
Antibiotic + ClAgNPs (µg/mL) 6.4 ± 4.2 6.2 ± 2.4
EcAgNPs (µM) 0.438 ± 0.18 3.75 ± 3.65
Antibiotic + EcAgNPs (µg/mL) 0.48 ± 0.37 0.5 ± 0.27
Figure 5. MIC of NPs in combination with ampicillin and carbenicillin (** p value: <0.01).
Statistical differences were found, for S. pseudintermedius, between the combination ampicillin +
ClAgNPs and the same antibiotic adjuvated with EcAgNPs (p-value = 0.002). Similarly, for P. aeruginosa,
carbenicillin showed lower MIC when in synergistic combination with EcAgNPs instead of ClAgNPs
(p-value = 0.0023).
3.3. Antibiofilm Properties
The formation of biofilm is a highly coordinated process during which bacteria adhere to each
other and biotic/abiotic surfaces, resulting in the formation of a complex community enclosed in a
self-produced extracellular matrix.
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Following preliminary assays for the screening of biofilm-forming ability (Figure S1), 8 and 7 strains
among, respectively, P. aeruginosa and S. pseudintermedius, were selected for their biofilm-forming ability.
These strains were grown for 24 h in microtiter plates and then exposed to ClAgNPs and EcAgNPs
following a 1:20 dilution. The results (Figure 6) confirm the anti-biofilm ability of silver nanoparticles,
but only for P. aeruginosa strains, the inhibition was statistically significant (p < 0.05) between the
non-treated group and both nanoparticles. For staphylococcal strains, no differences were found
between NT and both nanoparticles.
Figure 6. Anti-biofilm properties of NPs. Statistical differences were found only among Pseudomonas
strains (*** p-value: <0.001).
4. Discussion
In this study, the nanoparticles produced by Curcuma powder and E. coli showed heterogeneous
dimensions, as observed in previous studies [16,18,25,26]. However, particle dimensions were different
(11.107 ± 2.705 nm for C. longa and 27.282 ± 2.68 nm for E. coli) from those observed in the literature
in which NPs ranged from 6.3–2.64 nm [16] to 50 nm [25]. One possible explanation could be the
differences in terms of raw material used (e.g., quality of Curcuma powder) and the bacterial strain used
as reported in the literature [32]. EcAgNPs showed a rough spherical morphology with a high-branched
symmetry that could be responsible for the lack of the characteristic peak at 440 nm [33,34].
The disk diffusion assay demonstrated the ability of NPs (alone or in combination with antibiotics)
to kill more easily antibiotic-resistant bacteria. In particular, statistical differences were found in
S. pseudintermedius between nanoparticles from E. coli and Curcuma underlying the major effect
of bacterial-derived nanoparticles. These results allow us to hypothesize that nanoparticles are
broad-spectrum agents, as described in the literature [35]. It has to be noted that in the specific case
of S. pseudintermedius, the strains that resulted were resistant to ampicillin also after the addition
of nanospheres, whereas P. aeruginosa strains became susceptible to carbenicillin after NPs addition.
The MIC values are in agreement with the literature in which NPs are reported as being more active
against Gram-negative bacteria [18]. From the comparison of ClAgNPs and EcAgNPs between
S. pseudintermedius and P. aeruginosa, only EcAgNPs were found to be statistically different in
S. pseudintermedius; these results seem to be in contrast with MIC values, but could be explained by the
presence of E.coli protein residues (used for the synthesis of EcAgNPs) present on the surface of NPs
that could interfere with the staphylococcal growth [36]. It is well documented that the quorum-sensing
pathways devoted to bacterial growth, communication and expression of virulence factors, are linked
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to the expression of species-specific peptides, experimentally peptides derived from Gram-negative
bacteria can inhibit the growth or expression of specific proteins of Gram-positive [37]. One of the
possible mechanisms by which silver nanoparticles exert their antimicrobial activity is the adhesion
to the cell wall and subsequently breaking of this structure, leading the antibiotic to enter, and more
easily continue to destroy the cell wall [7,19]. After the entrance, NPs can cause direct damages to
proteins and DNA via reactive oxygen species (ROS) production [18].
One of the most studied bacterial virulence factors is the ability to produce biofilm through the
quorum-sensing communication system. Biofilm development is related to environmental signals and
communication systems that reflect on specific gene expression [38]. Nanoparticles from both Curcuma
and bacterial synthesis can destroy the mature biofilm of Pseudomonas. The reason for this higher activity
could be the adsorption of biomolecules on the surface of bacteria due to electrostatic attraction [14].
The synthesized AgNPs showed antibacterial activity alone and in combination with common
antibiotics, suggesting a potential use as alternative therapies in case of Multi Drug Resistant-derived
infections. However, their ability to destroy mature biofilm has to be properly studied in terms of
localization and elaboration of other nanoparticles-based approaches.
Supplementary Materials: The following are available online at http://www.mdpi.com/2306-7381/7/1/12/s1,
Figure S1: Biofilm forming ability of Pseudomonas and Staphylococcus strains.
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